[1] 中国免疫学会神经免疫学分会. 重症肌无力诊断和治疗中国专家共识[J]. 中国神经免疫学和神经病学杂志, 2012,6(19):401-408. [2] 韩曙光,吕蕾,赵弘卿,等. 重症肌无力患者并发呼吸衰竭的影响因素及其预后相关因素研究[J]. 实用心脑肺血管病杂志,2015,23(10):32-35. [3] Van Berkel M A, Twilla J D, England B S. Emergency Department Management of a Myasthenia Gravis Patient with Community- Acquired Pneumonia: Does Initial Antibiotic Choice Lead to Cure or Crisis?[J]. J Emerg Med,2016,50(2):281-285. [4] Ramos-Fransi A, Rojas-Garcia R, Segovia S, et al.Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry[J]. Eur J Neurol, 2015,22(7): 1056-1061. [5] Gui M, Luo X, Lin J, et al.Long-term outcome of 424 childhood- onset myasthenia gravis patients[J].J Neurol,2015, 262(4):823-830. [6] 徐仙女. 重症肌无力患者肺部感染临床分析[J]. 中华医院感染学志,2011,21(4):687-688. [7] Gilhus N E, Romi F, Hong Y, et al.Myasthenia gravis and infectious disease[J].J Neurol,2018,265(6):1251-1258. [8] Dhand U K.Clinical approach to the weak patient in the intensive care unit[J]. Respir Care, 2006,51(9):1024-1041. [9] 王美霞. 氨基糖苷类药物的不良反应及综合防治对策[J]. 中国实用医药, 2016,11(2):269-270. [10] 邓敏, 胡芳, 王云甫,等. 头孢菌素类、喹诺酮类和氨基糖苷类抗菌药物对重症肌无力影响研究[J]. 中国感染控制杂志, 2005,4(1):4-8. [11] 张慧颖. 临床常见非合理用药[M]. 4版.北京: 人民卫生出版社, 2010:601-602. [12] Hokkanen E.Antibiotics in myasthenia gravis[J]. Br Med J, 1964,1(5390):1111-1112. [13] Hokkanen E.The aggravating effect of some antibiotics on the neuromuscular blockade in myasthenia gravis[J]. Acta Neurol Scand, 1964,40(4):346-352. [14] Hussain N, Hussain F, Haque D, et al.A diagnosis of late- onset myasthenia gravis unmasked by topical antibiotics[J]. J Community Hosp Intern Med Perspect, 2018,8(4):230-232. [15] Maramattom B V, Wijdicks E F.Acute neuromuscular weakness in the intensive care unit[J]. Crit Care Med, 2006,34(11): 2835-2841. [16] Deng M, Wang Y F, Hu F, et al.Effect of different kinds of antibiotics on transmission function at the neuromuscular junction in mice with myasthenia gravis[J]. Chin J Clin Rehabil,2005,17(9):233-235. [17] Sieb J P.Fluoroquinolone antibiotics block neuromuscular transmission[J]. Neurology, 1998,50(3):804-807. [18] FDA. Risk of Fluoroquinolone-associated Myasthenia Gravis Exacerbation February 2011 Label Changes for Fluoroquinolones [EB/OL]. (2011-03-15)[2019-02-12]. https://wayback. archive-it.org/7993/20170112174719/http://www.fda.gov/ Safety/MedWatch/SafetyInformation/ucm247115.htm. [19] 国家食品药品监督管理总局. 药物警戒快讯[EB/OL]. (2012-05-16)[2019-02-12]. http://www.cdr-adr.org.cn/ yxaqjs/gj/201205/t20120516_4990.html. [20] 谢欢, 陈颖, 韦凤. 喹诺酮类药物诱发/加重重症肌无力个案汇总分析[J]. 中国药物应用与监测, 2018,15(1): 24-27. [21] 林艾羽. 莫西沙星致重症肌无力患者发生肌无力危象一例报告[C]//第十一次中国中西医结合神经科学术会议论文汇编.河北:中国中西医结合学会,2015:329-330. [22] Amitabh V, Singhal A, Kumar S, et al.Efficacy and safety of oral gemifloxacin for the empirical treatment of pneumonia[J]. Lung India, 2012,29(3):248-253. [23] 毕煌垒, 张佳岳, 刘晓慧,等. 新型广谱氟喹诺酮类抗菌药物—德拉沙星[J]. 临床药物治疗杂志, 2017,15(7): 6-10. [24] 苗贝贝, 梁蓓蓓, 王睿,等. 新型无氟喹诺酮类药物奈诺沙星的研究进展[J]. 中国医院用药评价与分析, 2016,16(11): 1577-1580. [25] Absher J R, Bale J J.Aggravation of myasthenia gravis by erythromycin[J]. J Pediatr, 1991,119(1):155-156. [26] May E F, Calvert P C.Aggravation of myasthenia gravis by erythromycin[J]. Ann Neurol, 1990,28(4):577-579. [27] 王菲菲,于双得,王红菊.阿奇霉素致重症肌无力加重1 例[J]. 药物流行病学杂志, 2017,26(10):682. [28] 张颖, 童庆伟. 阿奇霉素致重症肌无力危象1例[J]. 临床荟萃, 2010,17(25):1548. [29] Ross D B.The FDA and the case of Ketek[J]. N Engl J Med, 2007,356(16):1601-1604. [30] Bertrand D, Bertrand S, Neveu E, et al.Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors[J]. Antimicrob Agents Chemother, 2010,54(12):5399-5402. [31] Liu C N, Somps C J.Telithromycin blocks neuromuscular transmission and inhibits nAChR currents in vitro[J]. Toxicol Lett, 2010,194(3):66-69. [32] Van Bambeke F.Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones[J]. Ann Med, 2014,46(7):512-529. [33] Garrido-Mesa N, Zarzuelo A, Gálvez J.Minocycline: far beyond an antibiotic[J]. Br J Pharmacol, 2013,169(2):337-352. [34] Roper J, Fleming M E, Long B, et al.Myasthenia Gravis and Crisis: Evaluation and Management in the Emergency Department[J]. J Emerg Med, 2017,53(6):843-853. [35] 刘晓东, 谢思宁, 菅凌燕,等. 替加环素不良反应的文献计量分析[J]. 中国新药杂志, 2017,26(19):2364-2368. [36] Argov Z, Brenner T, Abramsky O.Ampicillin may aggravate clinical and experimental myasthenia gravis[J]. Arch Neurol, 1986,43(3):255-256. [37] Sonawalla A B, Lance J W.Relapse of myasthenia gravis after amoxycillin therapy[J].J Pak Med Assoc, 1989,39(1): 18-19. [38] O’Riordan J, Javed M, Doherty C, et al. Worsening of myasthenia gravis on treatment with imipenem/cilastatin[J]. J Neurol Neurosurg Psychiatry, 1994,57(3):383. [39] Jones S C, Sorbello A, Boucher R M.Fluoroquinolone- associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review[J]. Drug Saf, 2011, 34(10):839-847. [40] 南李, 叶晓芬, 蔡映云,等. 1例重症肌无力合并咳嗽变异性哮喘及肺部感染患者的用药分析[J]. 上海医药, 2016, 37(21):63-65. [41] Elsayed M G, Elkomy A A, Elbadawy M.Some Pharmacodynamic Aspects of Cefepime[J]. J Pharm (Cairo), 2013,2013:381910. [42] Grill M F, Maganti R K.Neurotoxic effects associated with antibiotic use: management considerations[J]. Br J Clin Pharmacol, 2011,72(3):381-393. [43] Nguyen C T, Nanfro J.Probable vancomycin-induced myasthenic crisis: a case report[J]. J Antimicrob Chemother, 2018,73(4):1106-1108. [44] Pittinger C B, Eryasa Y, Adamson R.Antibiotic-induced paralysis[J]. Anesth Analg, 1970,49(3):487-501. [45] Torres A, Zhong N, Pachl J, et al.Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial[J].Lancet Infect Dis, 2018,18(3):285-295. [46] Wagenlehner F M, Umeh O, Steenbergen J, et al.Ceftolozane- tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)[J].Lancet, 2015,385(9981):1949-1956. |